ArticleThe Journal of clinical investigation2025

An FDA-approved drug structurally and phenotypically corrects the K210del mutation in genetic cardiomyopathy models.

Ping Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.